Cepheid Acquires Swedish PCR Dx Kit Shop Sangtec for $27M in Cash | GenomeWeb
NEW YORK (GenomeWeb News) — Cepheid today said it has acquired PCR diagnostics company Sangtec Molecular Diagnostics from Altana Pharma for around $27 million in cash.   
Cepheid CEO John Bishop said the acquisition gives the company a “relatively complete line of products for managing infections of immunocompromised patients.”  
 
Bishop said the firm will also provide Cepheid with an established reagent-manufacturing base in Europe.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: genetic target for urothelial bladder cancer treatment, and more.

At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.

Two dozen scientific organizations have endorsed the March for Science, according to ScienceInsider.

Researchers in Japan describe a chimpanzee with a chromosomal abnormality similar to human Down syndrome, Mashable reports.